Cogent Biosciences, Inc. (COGT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 290.72M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 60.37M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -389.09M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $290.72M | (m) | $60.37M | $-389.09M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $282.12M | (m) | $52.98M | $-362.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $269.78M | (m) | $46.08M | $-333.36M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $256.27M | (m) | $40.30M | $-307.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $250.89M | (m) | $40.06M | $-299.66M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $242.98M | (m) | $40.35M | $-288.47M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $232.66M | (m) | $39.74M | $-275.94M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $219.33M | (m) | $38.61M | $-260.43M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $205.84M | (m) | $37.01M | $-244.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $190.42M | (m) | $34.16M | $-227.30M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $173.75M | (m) | $30.62M | $-208.13M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $161.78M | (m) | $26.81M | $-193.65M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $141.59M | (m) | $22.67M | $-170.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $132.19M | (m) | $20.04M | $-159.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $121.63M | (m) | $18.37M | $-147.84M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $105.40M | (m) | $17.18M | $-129.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $90.26M | (m) | $16.02M | $-112.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $73.17M | (m) | $14.08M | $-94.17M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $55.91M | (m) | $11.69M | $-75.55M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $41.51M | (m) | $8.70M | $-61.37M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $31.71M | (m) | $8.75M | $-98.75M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $24.45M | (m) | $7.03M | $-88.86M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $25.74M | (m) | $6.02M | $-82.20M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $29.98M | (m) | $5.99M | $-68.50M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $35.32M | (m) | $3.27M | $-23.34M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $40.80M | (m) | $3.28M | $-26.48M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $43.71M | (m) | $3.24M | $-32.18M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $44.12M | (m) | $3.30M | $-43.42M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $44.04M | (m) | $3.37M | $-41.96M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $42.55M | (m) | $3.33M | $-40.86M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $38.28M | (m) | $3.09M | $-36.01M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $29.83M | (m) | $1.34M | $-26.15M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |